Birchview Capital
Latest statistics and disclosures from Birchview Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BMY, NBIX, AZYO, QDEL, ACAD, and represent 59.94% of Birchview Capital's stock portfolio.
- Added to shares of these 10 stocks: AZYO (+$8.0M), INBX, DCGO, NBIX, GOSS, Soleno Therapeutics, TSVT, AVEO, BHVN, SILK.
- Started 6 new stock positions in TSVT, DCGO, VTYX, SILK, INBX, PHR.
- Reduced shares in these 10 stocks: BMY, Acceleron Pharma, Arena Pharmaceuticals, PGNY, BIIB, TGTX, PROG, VNDA, FHTX, ARQT.
- Sold out of its positions in Acceleron Pharma, ARQT, Arena Pharmaceuticals, PROG, PGNY, TGTX, TXMD.
- Birchview Capital was a net buyer of stock by $6.5M.
- Birchview Capital has $139M in assets under management (AUM), dropping by -5.48%.
- Central Index Key (CIK): 0001618205
Tip: Access up to 7 years of quarterly data
Positions held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Birchview Capital
Companies in the Birchview Capital portfolio as of the March 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Bristol Myers Squibb (BMY) | 39.6 | $55M | -5% | 754k | 73.03 | |
| Neurocrine Biosciences (NBIX) | 6.0 | $8.4M | +11% | 89k | 93.75 | |
| Aziyo Biologics (AZYO) | 6.0 | $8.3M | +2735% | 1.4M | 5.84 | |
| Quidel Corporation (QDEL) | 4.8 | $6.7M | 60k | 112.46 | ||
| ACADIA Pharmaceuticals (ACAD) | 3.5 | $4.8M | 199k | 24.22 | ||
| Foghorn Therapeutics (FHTX) | 3.2 | $4.5M | -6% | 294k | 15.23 | |
| Albireo Pharma (ALBO) | 2.4 | $3.4M | 113k | 29.83 | ||
| Accelr8 Technology (AXDX) | 2.3 | $3.2M | 2.3M | 1.44 | ||
| United Therapeutics Corporation (UTHR) | 2.3 | $3.2M | 18k | 179.39 | ||
| Continental Resources (CLR) | 1.7 | $2.4M | 39k | 61.32 | ||
| Biogen Idec (BIIB) | 1.5 | $2.1M | -19% | 10k | 210.59 | |
| Biodesix (BDSX) | 1.5 | $2.1M | +13% | 1.3M | 1.69 | |
| Karyopharm Therapeutics (KPTI) | 1.4 | $2.0M | +9% | 269k | 7.37 | |
| Encana Corporation (OVV) | 1.3 | $1.8M | 34k | 54.06 | ||
Setup an alertBirchview Capital will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Biohaven Pharmaceutical Holding (BHVN) | 1.2 | $1.7M | +40% | 14k | 118.57 | |
| Prothena Corp SHS (PRTA) | 1.1 | $1.5M | +4% | 42k | 36.57 | |
| Masimo Corporation (MASI) | 1.0 | $1.4M | +16% | 9.3k | 145.58 | |
| Alkermes SHS (ALKS) | 0.9 | $1.3M | 50k | 26.32 | ||
| Harrow Health (HROW) | 0.9 | $1.2M | 180k | 6.82 | ||
| Corcept Therapeutics Incorporated (CORT) | 0.8 | $1.1M | 50k | 22.52 | ||
| Inhibrx (INBX) | 0.8 | $1.1M | NEW | 50k | 22.28 | |
| Equitrans Midstream Corp (ETRN) | 0.8 | $1.1M | 133k | 8.44 | ||
| Gossamer Bio (GOSS) | 0.8 | $1.1M | +222% | 129k | 8.68 | |
| Docgo (DCGO) | 0.7 | $1.0M | NEW | 110k | 9.25 | |
| Arvinas Ord (ARVN) | 0.7 | $1.0M | 15k | 67.33 | ||
| Amarin Corp Spons Adr New (AMRN) | 0.7 | $987k | 300k | 3.29 | ||
| Pioneer Natural Resources (PXD) | 0.7 | $950k | 3.8k | 250.00 | ||
| Cytokinetics (CYTK) | 0.7 | $920k | 25k | 36.80 | ||
| ImmunoGen (IMGN) | 0.7 | $904k | 190k | 4.76 | ||
| Protagonist Therapeutics (PTGX) | 0.6 | $900k | 38k | 23.68 | ||
| Soleno Therapeutics | 0.6 | $820k | +319% | 3.7M | 0.22 | |
| Aveo Pharmaceuticals (AVEO) | 0.6 | $783k | +250% | 140k | 5.59 | |
| Contrafect | 0.5 | $730k | 200k | 3.65 | ||
| Inari Medical Ord (NARI) | 0.5 | $725k | +14% | 8.0k | 90.62 | |
| Nektar Therapeutics (NKTR) | 0.5 | $690k | +77% | 128k | 5.39 | |
| Irhythm Technologies (IRTC) | 0.5 | $630k | 4.0k | 157.50 | ||
| Apellis Pharmaceuticals (APLS) | 0.4 | $610k | 12k | 50.83 | ||
| Kalvista Pharmaceuticals (KALV) | 0.4 | $590k | 40k | 14.75 | ||
| 2seventy Bio (TSVT) | 0.4 | $586k | NEW | 34k | 17.07 | |
| Vanda Pharmaceuticals (VNDA) | 0.4 | $566k | -37% | 50k | 11.32 | |
| Chemocentryx (CCXI) | 0.4 | $501k | -20% | 20k | 25.05 | |
| Cullinan Oncology (CGEM) | 0.3 | $472k | 45k | 10.46 | ||
| Silk Road Medical Inc Common (SILK) | 0.3 | $413k | NEW | 10k | 41.30 | |
| Bluebird Bio (BLUE) | 0.3 | $407k | 84k | 4.85 | ||
| Zentalis Pharmaceuticals (ZNTL) | 0.3 | $369k | 8.0k | 46.12 | ||
| Amicus Therapeutics (FOLD) | 0.3 | $360k | 38k | 9.47 | ||
| Ventyx Biosciences (VTYX) | 0.2 | $339k | NEW | 25k | 13.56 | |
| Xencor (XNCR) | 0.2 | $328k | 12k | 26.67 | ||
| BioCryst Pharmaceuticals (BCRX) | 0.2 | $325k | 20k | 16.25 | ||
| Stoke Therapeutics (STOK) | 0.2 | $316k | 15k | 21.07 | ||
| G1 Therapeutics (GTHX) | 0.2 | $304k | 40k | 7.60 | ||
| Kiniksa Pharmaceuticals (KNSA) | 0.2 | $298k | 30k | 9.93 | ||
| Phreesia (PHR) | 0.2 | $264k | NEW | 10k | 26.40 | |
| Iveric Bio (ISEE) | 0.2 | $252k | 15k | 16.80 | ||
| Turning Point Therapeutics I (TPTX) | 0.2 | $215k | 8.0k | 26.88 | ||
| Inflarx Nv (IFRX) | 0.1 | $128k | 70k | 1.83 | ||
| Angion Biomedica Corp (ANGN) | 0.1 | $115k | 54k | 2.11 | ||
| Aspira Womens Health (AWH) | 0.1 | $107k | 103k | 1.04 | ||
| Laird Superfood (LSF) | 0.1 | $101k | +100% | 28k | 3.61 | |
| Yield10 Bioscience | 0.1 | $99k | 19k | 5.28 | ||
| Sientra (SIEN) | 0.1 | $89k | 40k | 2.23 | ||
| Concert Pharmaceuticals I equity (CNCE) | 0.0 | $67k | 20k | 3.35 | ||
| Akebia Therapeutics (AKBA) | 0.0 | $14k | -80% | 20k | 0.70 | |
Past Filings by Birchview Capital
SEC 13F filings are viewable for Birchview Capital going back to 2014
- Birchview Capital 2022 Q1 filed May 13, 2022
- Birchview Capital 2021 Q3 filed Nov. 12, 2021
- Birchview Capital 2021 Q2 filed Aug. 10, 2021
- Birchview Capital 2021 Q1 filed May 14, 2021
- Birchview Capital 2020 Q4 filed Feb. 9, 2021
- Birchview Capital 2020 Q3 restated filed Nov. 12, 2020
- Birchview Capital 2020 Q3 filed Nov. 12, 2020
- Birchview Capital 2020 Q2 restated filed Sept. 25, 2020
- Birchview Capital 2020 Q2 filed Aug. 10, 2020
- Birchview Capital 2020 Q1 filed May 12, 2020
- Birchview Capital 2019 Q4 filed Feb. 12, 2020
- Birchview Capital 2019 Q3 filed Nov. 12, 2019
- Birchview Capital 2019 Q2 filed Aug. 6, 2019
- Birchview Capital 2019 Q1 filed May 3, 2019
- Birchview Capital 2018 Q4 filed Feb. 6, 2019
- Birchview Capital 2018 Q3 filed Nov. 1, 2018